Cover Image

Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system

BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology. Pirfenidone (PFD) and nintedanib (NDN) were both conditionally recommended in the clinical practice guideline published in 2015. Safety and tolerability are related to the risk of t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiangyu Sun (Author), Huaguang Wang (Author), Xi Zhan (Author), Yuanyuan Yan (Author), Kun Chen (Author), Zhuoling An (Author), Hong Zhou (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
by: KM Roach, et al.
Published: (2021)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
by: Ying Zhang, et al.
Published: (2023)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021)

Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system
by: Chunyan Wei, et al.
Published: (2024)

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis
by: Zheng Zhang, et al.
Published: (2024)

South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
by: Wenting Zhang, et al.
Published: (2024)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases
by: Shupeng Zou, et al.
Published: (2024)

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
by: Huqun Li, et al.
Published: (2024)

No drug-drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
by: Wonsuk Shin, et al.
Published: (2024)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS)
by: Victor Pera, et al.
Published: (2023)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021
by: Christine Learned, BA, et al.
Published: (2022)

Analysis of Adverse Events and Medical Errors in Long-Term Hormone Treatments for Endometriosis: A Study Based on the US Food and Drug Administration Event Reporting System
by: Zhang Y, et al.
Published: (2022)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios
by: Daniel N. A. Ankrah, et al.
Published: (2018)

Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database
by: Jinhua Chen, et al.
Published: (2024)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023)

Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System
by: Takamasa Sakai, et al.
Published: (2022)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
by: Xiaoyin Bai, et al.
Published: (2021)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2024)

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis
by: Aidou Jiang, et al.
Published: (2024)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022)

Clinical, radiological, and serological assessment of the efficacy and safety of nintedanib compared to pirfenidone in a sample of Iraqi patients with idiopathic pulmonary fibrosis: A retrospective cohort study
by: Walaa Abdul Jabbar Al-Sarraf, et al.
Published: (2024)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
by: Zhou, Zeyun, et al.
Published: (2020)

Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS)
by: Daisuke Nango, et al.
Published: (2019)

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases
by: Qiaofang Liang, et al.
Published: (2024)